Published in the January 2014 issue of the American Journal of Obstetrics & Gynecology is a study finding that 17-hydroxyprogesterone caproate (“17P”), an injectable medication that is used to prevent prematurity, obtained from 15 compounding pharmacies throughout the United States “did not raise safety concerns when assessed for potency, sterility, pyrogen status, or impurities.”

4. Published in the January 2014 issue of the American Journal of Obstetrics & Gynecology is a study finding that 17-hydroxyprogesterone caproate (“17P”), an injectable medication that is used to prevent prematurity, obtained from 15 compounding pharmacies throughout the United States “did not raise safety concerns when assessed for potency, sterility, pyrogen status, or impurities.”  (17P is an unusual, possibly unique, case, in that it is a medicine that is FDA-approved–sold under the brand-name Makena–but also available in compounded form.  For background, see here.)   In an editorial accompanying the AJOG study, Arnold Parry and Samuel Cohen write that “it is critical for obstetrical providers to understand that the cost of compounded 17P is much lower than that of the FDA-approved product, and many patients will have limited access to the FDA-approved product based on their insurance coverage.”

quoted from here